Mereo Biopharma Group PLC
NASDAQ:MREO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.9
4.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mereo Biopharma Group PLC
Mereo Biopharma Group PLC
Accumulated Depreciation
Mereo Biopharma Group PLC
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Accumulated Depreciation
-£2.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Accumulated Depreciation
-$462k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Accumulated Depreciation
-$28.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accumulated Depreciation
-$19.7m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accumulated Depreciation
-£52.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mereo Biopharma Group PLC
Glance View
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).
See Also
What is Mereo Biopharma Group PLC's Accumulated Depreciation?
Accumulated Depreciation
-2.1m
GBP
Based on the financial report for Dec 31, 2023, Mereo Biopharma Group PLC's Accumulated Depreciation amounts to -2.1m GBP.
What is Mereo Biopharma Group PLC's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-5%
Over the last year, the Accumulated Depreciation growth was -38%. The average annual Accumulated Depreciation growth rates for Mereo Biopharma Group PLC have been -5% over the past three years .
You don't have any saved screeners yet
